Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Unresectable Hepatocellular Carcinoma × durvalumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 4 Lung Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Unresectable Hepatocellular Carcinoma 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcopenia 1 Recurrent Squamous Cell Lung Carcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Oropharyngeal Neoplasms 1 Non-Small Cell Lung Cancer NSCLC 1 Neoplasms 1 Melanoma 1 Kidney Neoplasms 1 Hepatobiliary Cancers 1 Head and Neck Neoplasms 1 Deglutition Disorders 1

Interventions

tremelimumab 1 durvalumab 1 atezolizumab 1 Therapeutics 1 Immunotherapy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06117891 2025-11-12

REFINE-IO

Bayer

Gastrointestinal

Unresectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡